dihydroergotamine   Click here for help

GtoPdb Ligand ID: 121

Synonyms: D.H.E. 45® | Migranal®
Approved drug PDB Ligand
dihydroergotamine is an approved drug (FDA (1997))
Compound class: Synthetic organic
Comment: Dihydroergotamine is an ergot alkaloid. It is used as a vasoconstrictor. The drug is administered as dihydroergotamine mesylate (PubChem CID 71171). The use of ergot alkaloids in the clinic has been discontinued or restricted due to their propensity to cause fibrosis.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 118.21
Molecular weight 583.28
XLogP 2.29
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CN1CC(CC2C1Cc1c[nH]c3c1c2ccc3)C(=O)NC1(C)OC2(N(C1=O)C(Cc1ccccc1)C(=O)N1C2CCC1)O
Isomeric SMILES CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O
InChI InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1
InChI Key LUZRJRNZXALNLM-JGRZULCMSA-N
No information available.
Summary of Clinical Use Click here for help
Dihydroergotamine is used to treat migraine and cluster headaches. In 2020, a nasally administered dry-powder formulation of dihydroergotamine (STS101; Satsuma Pharmaceuticals) failed to show efficacy above placebo in phase 3 trial, as a treatment for acute migraine. STS101 was intended to improve upon the bioavailability and pharmacokinetics of the nasally administered formulation of dihydroergotamine in Migranal®.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The anti-migraine activity of dihydroergotamine is believed to be due to its high affinity binding to serotonin 5-HT1D receptors on intracranial blood vessels (causes vasoconstriction and headache relief) and on sensory nerve endings of the trigeminal system (inhibits release of pro-inflammatory neuropeptides)
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04406649 A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine Phase 3 Interventional Satsuma Pharmaceuticals, Inc.
NCT03901482 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine Phase 3 Interventional Satsuma Pharmaceuticals, Inc.
External links Click here for help
For extended ADME data see the following:

Drugs.com